TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia
C. Lai, J. Vadakekolathu, S. Reeder, S. E. Church, T. Hood, I. Aldoss, J. Godwin, M. J. Wieduwilt, M. Arellano, J. Muth, F. Ravandi, K. Sweet, H. Altmann, G. A. Foulds, F. Stolzel, , S. Rutella
This paper shows TP53 mutations in AML are linked to immune features and improved response to flotetuzumab immunotherapy.
bioRxiv · Feb 28, 2020 · PreprintImmunology